Fig. 2.

Testing of shRNA screening hit–specific drugs reveals LB-100 and FGFR inhibitors as potent drug candidates for DIPGs. (A) Heatmap illustrating cell viability after treatment for 72 hours with increasing concentrations of 21 different inhibitors specified in Table 1, as exemplified by DIPG-XXV. Inhibitors are sorted according to their IC₅₀ values, whereas n/a indicates that the IC₅₀ could not be determined. Asterisks (*) indicate that drug responses displayed high variability. FGFR inhibitors, including ponatinib and the PP2A inhibitor LB-100 showed highest efficacy, with lowest IC₅₀ values. (B) Dose-response curves and corresponding mean IC₅₀ values of 72 hours ponatinib or LB-100 treatment of DIPG (green) and GBM (orange) cell cultures as well as human astrocyte control cells (gray). Both drugs showed highest efficacy in GBM-001 and DIPG cell cultures, whereas human astrocytes and pcGBM2 cells were less affected. IC₅₀ curves and bars represent mean ± SD of 3 independent experiments.